• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Provided is an agent for reducing odors of pyrazine derivatives based on an olfactory receptor antagonism. The agent for reducing odors of pyrazine derivatives includes at least one antagonist of olfactory receptor OR5K1 as an active ingredient.
    公开号:AU2012379961A1
    申请号:U2012379961
    申请日:2012-12-29
    公开日:2014-09-25
    发明作者:Michiaki Inoue；Aya Kato；Kayoko NOMIZU；Naoko Saito
    申请人:Kao Corp；
    IPC主号:C07D241-12
    专利说明:
    WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application AGENT FOR INHIBITING ODOR OF PYRAZINE DERIVATIVES [0001] Cross reference to related application This application claims priority from U.S. Provisional Patent Application No. 61/596,963 filed on February 9, 2012, which is incorporated herein by reference in its entirety. Field of the Invention [0002] The present invention relates to an agent for inhibiting an odor of a pyrazine derivative. Background of the Invention [00031 .There are a large number of malodorous molecules having different polarities and molecular weights in our living environment. Hitherto, a variety of methods have been developed for reducing various malodorous molecules. In general, the methods for reducing malodors are roughly classified into biological methods, chemical methods, physical methods, and sensory methods. Among malodorous molecules, short-chain fatty acids and amines having high polarities can be reduced by chemical methods, i.e., neutralization. Sulfur compounds such as thiol can be reduced by physical methods, i.e., absorptive treatment. - 1 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-078OWO00) Specification of PCT Application However, there are still many malodorous molecules which cannot be reduced by known malodor reducing methods. [00041 In addition, the known malodor reducing methods by the chemical neutralization or the absorptive treatment take long time for reducing the amounts of malodorous substances and thereby lack immediate effect. A method of reducing malodor by using an aromatic and thereby providing strong perception of another odor is also known. However, the odor of the aromatic may cause discomfort in this method. Moreover, these known methods may get rid of odors other than the target malodors. Thus, there is a demand for a malodor reducing method which can overcome these problems. [0005] In mammals including humans, the mechanism for odorant recognition includes binding odorant molecules to olfactory receptors present on olfactory sensory neurons included in the olfactory epithelium, which is present in an upper portion of the nasal cavity, and transmitting the response of the receptors to the central nervous system. It has been reported that, 387 different olfactory receptors are present in human, and the genes encoding these olfactory receptors account for about 3% of the human genome. In general, a plurality of olfactory receptors responds to a plurality of odorant molecules. Specifically, one single olfactory receptor responds to a plurality of structurally similar odorant molecules at - 2 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application different affinities, while one single odorant molecule is detected by a plurality of olfactory receptors. It is also reported that a certain odorant molecule which can activate one olfactory receptor serves as an antagonist which inhibits activation of another olfactory receptor. Such combined response of these olfactory receptors leads to recognition of each odor. [0006] Thus, when a first odorant molecule is co-present with a second odorant molecule, in some cases, the response of an olfactory receptor to the first odorant molecule is inhibited by the second odorant molecule. Through the inhibition, the odor of the first odorant molecule recognized by olfactory receptors may.vary considerably. This mechanism is called "olfactory receptor antagonism." Odor modulation by olfactory receptor antagonism can inhibits recognition specific to a malodor, and therefore differs in mechanism from a malodor reducing method by adding a perfume, an aromatic, or a like substance to the target odorant. In addition, the odor of an aromatic causing an unpleasant sensation to users can be prevented. Therefore, odor modulation based on olfactory receptor antagonism is a preferred means for reducing malodor. [0007] In order to mask a malodor with an odor of, for example, a perfume or an aromatic, it is necessary to identify an odor substance exhibiting an effective - 3 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application malodor reducing function on the target malodorous substance. Hitherto, odors have been evaluated through a sensory test by specialists. However, the sensory test has problems. The problems include for example, odor evaluators must be trained, and the throughput of the test is low. Thus, identification of an odor substance exhibiting a malodor reducing function is not easy. [0008] A skin tanning agent (also called a self-tanning agent or a sunless tanning agent) is a skin cosmetic for staining the skin. As a component for providing skin with a brown color, dihydroxyacetone (DHA) is mainly used alone or together with, for example, erythrulose. These components react with the upper layer of the skin to change the color of skin to brown. This staining probably progresses by a browning reaction, but the details of the reaction mechanism have been hardly clarified. The browning reaction is also called a Maillard reaction in the food chemistry field and is a term referring to a reaction for generating a brown polymer called melanoidin by polymerizing a nitrogen containing compound, such as an amino acid or a protein, and a reducing sugar. The Maillard reaction is caused by, for example, heating of a food and is involved in coloring of the food and generation of a flavor component. [0009] Pyrazines are known to be generated by the Maillard reaction and as a component of a roasted aroma of a food. - 4 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application Patent Document 1 describes an odor-blocking agent including a functional pyrazine compound as an active ingredient for blocking the odor of an alkylpyrazine compound. Pyrazines are usually used as flavoring agents for flavoring foods, and the odors of pyrazines are rather utilized. In the food field, odors obtained by the Maillard reaction are reported in Non-Patent Document 1. In Non-Patent Document 1, the pyrazine compound is described as a preferred odor which characterizes a food. For example, 2,6-dimethylpyrazine is described as having a "sweet, fried, resembling fried potatoes, nutty, roasted" odor. Prior art Patent Documents [0010] [Patent Document 1] JP-A-2003-024423 Non-Patent Documents [0011] [Non-Patent Document 1] S. Fors, Sensory Properties of Volatile Maillard Reaction Products and Related Compounds, "The Maillard Reaction in Foods and Nutrition" (ACS Symposium Series, Vol. 215), Chapter 12, pp. 185-286 Publication Date (Print): April 29, 1983 Summary of the Invention [0012] -5- WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application The present invention provides use of at least one compound selected from the group consisting of compounds described in Table 1 below, for reducing an odor of a pyrazine derivative. The present invention also provides a method of reducing an odor of a pyrazine derivative, wherein the method includes coexisting an odor of a pyrazine derivative with at least one compound selected from the group consisting of compounds described in Table 1 below. The present invention further provides an agent for reducing an odor of a pyrazine derivative, including at least one antagonist against olfactory receptor OR5K1 as an active ingredient, wherein the antagonist is selected from the group consisting of compounds described in Table 1 below. [0013] -6- WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application [Table 11 2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2 buten-1-ol 5-methyl-2-(1-methylethyl)-phenol 3,7-dimethyl-2,6-octadienal phenylethyl salicylate 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2 naphthalenyl)-ethanone isolongifolanone 4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one (a-ionone) 4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-2-one (p-ionone) vetiverol 7-acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7 tetramethyl-naphthalene a-amylcinnamic aldehyde a-methyl-4-(1-methylethyl)-benzenepropanal 4-methyl-3-decen-5-ol 1-(2-tert-butylcyclohexyloxy)-2-butanol 2-methoxy-1-(phenylmethoxy)-4-(1-propenyl)-benzene a-methyl-p-(p-tert-butylphenyl)-propionaldehyde 1(-)-menthol o-6-hexadecenelactone 2-(2-(4-methyl)-3-cyclohexen-1-yl) propylcyclopentanone formaldehyde cyclododecyl ethyl acetal 1-(2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-lH-3a,7 methanoazulen-5-yl)-ethanone P-methyl naphthyl ketone
    -
    7- WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application (Table 1 cont'd) cedryl acetate (5E) -3-methylcyclopenta-5-decen--one cinnamaldehyde 4- (1-ethoxyvinyl) -3,3,5, 5-tetramethylcyclohexanone a-hexylcinnamic aldehyde 2-phenylpropionaldehyde 3, 7-dimethyl-6-octenal dodecahydro-3a, 6, 6, 9a-tetramethylnaphtho [2, 1-b] furan 4, 7, 7-trimethyl-spirobicyclo [2.2.1]heptane-2,1 cyclopentan-3-one a-isomethyl ionone 3,7-dimethyl-1-octanol cedryl methyl ether muscone 2-methyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2 buten-1-ol 2-cyclohexylpropanal y-undecalactone Cyclopentadecanolide 1- (2,6,6-trimethyl-1,3-cyclohexadien-1-yl)-2-buten-1 one 2, 4-dimethyl-3-cyclohexene-l-carboxyaldehyde 2,4, 6-trimethyl-3-cyclohexene-l-carboxyaldehyde 3,5, 6-trimethyl-3-cyclohexene-l-carboxyaldehyde 6,10-dimethyl-3-oxa-9-undecenal dimethyl benzyl carbinyl acetate ethyl- (3aa, 4a, 7a, 3aa) -octahydro-4, 7-methano-3aH indene-3a-carboxylate -8- WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780WO00) Specification of PCT Application (Table 1 cont'd) 2-pentyl-3-methyl-2-cyclopenten-1-one phenylhexanol 1-(5,5-dimethyl-l-cyclohexen-1-yl)-4-penten-1-one 6-tert-butyl-1,1-dimethylinden-4-yl methyl ketone cis-4-isopropylcyclohexylmethanol 1-allyl-3-methoxy-4-hydroxybenzene (E)-3,7-dimethyl-2,6-octadien-l-ol 4-tert-butyl-2,6-dimethyl-3,5-dinitroacetophenone 1,4-dioxacycloheptadecane-5,17-dione hexyl salicylate cx-methyl-3,4-methylenedioxyhydrocinnamic aldehyde Brief Description of the Drawings [0014] Fig. 1 shows responses of olfactory receptor OR5K1 to various concentrations of 2,6-dimethylpyrazine, wherein n = 5 and error bar = ±SE; Fig. 2 shows responses of olfactory receptor OR5K1 to various concentrations of pyrazine compounds, wherein n = 3 to 5 and error bar = ±SE; and Fig. 3 shows effects of various compounds for reducing an odor of 2,6-dimethylpyrazine, wherein error bar = ±SE. Detailed Description of the Invention [0015] -9- WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780WO00) Specification of PCT Application A problem that the use of a commercially available skin tanning agent (self-tanning agent or sunless tanning agent) involves a characteristic unpleasant odor expressed as, for example, an earthy or burnt sugar odor has been reported (D. M. Hindenlang and M. E. McDonnell, Cosmetics & Toiletries magazine, 2008, Vol. 123, No. 7, pp. 67-74), and there has been a demand for improvement thereof. The cause of the unpleasant odor was investigated to reveal that dimethylpyrazine, which is generated when dihydroxyacetone (DHA) or erythrulose in a skin tanning agent reacts with the skin to change the color of skin to brown, is one of causative substances. Furthermore, it revealed that, in addition to dimethylpyrazine, other pyrazine derivatives yield similar odors, and there is a demand for reducing the odors of these pyrazine derivatives. [0016] In order to attain the olfactory receptor antagonism, an olfactory receptor which responds to a target malodorous substance must be determined, and a substance which effectively exhibits an antagonistic effect on an olfactory receptor of malodorous substance must be searched and identified. Accordingly, the present inventors searched for an olfactory receptor which responds to a pyrazine derivative and succeeded in identification of the receptor. Furthermore, the present inventors found that the substance which inhibits response of the olfactory receptor can reduce the odor of - 10 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application the pyrazine derivative through masking by the olfactory receptor antagonism. [0017] According to the present invention, odors of pyrazine derivatives, for example, the odor which is generated in the use of a known self-tanning agent (also called a sunless tanning agent) can be specifically reduced without causing problems occurring in known malodor reducing methods using a deodorant or an aromatic, such as lack of immediate effect and discomfort due to the odor of the aromatic. [0018] As used herein, the term "masking" in the odor related field generally refers to means for inhibiting or weakening recognition of a target odor. The term "masking" may encompass chemical means, physical means, biological means, and sensory means. Examples of the masking means include any means for removing a odorant molecule responsible for a target odor from the environment (e.g., adsorption and chemical decomposition of the odorant); means for preventing release of a target odor to the environment (e.g., sealing); and a method in which recognition of a target odor is reduced by adding another odorant such as a flavoring agent or an aromatic. [0019] As used herein, the term "masking through olfactory receptor antagonism" refers to one embodiment of the aforementioned broadly defined "masking" and is - 11 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application means for inhibiting the response of an olfactory receptor to a target odorant molecule by an additional odorant molecule, to thereby modulate the odor of the target odorant molecule recognized by a subject. Although masking through olfactory receptor antagonism employs an additional odorant molecule, the masking differs from means for canceling out a target odor by use of a strong odorant such as an aromatic. In one embodiment of masking through olfactory receptor antagonism, a substance which can inhibit the response of an olfactory receptor such as an antagonist is used. When a response-inhibiting substance which can specifically inhibit the response of a receptor related to recognition of a certain odor is employed, the response of the receptor is suppressed, whereby the odor recognized by a subject can be modulated. [0020] The present inventors identified olfactory receptor OR5K1 from many olfactory receptors as a sole receptor which responds to pyrazine derivatives. The response of OR5K1 to pyrazine derivatives has not been found until now, and OR5K1 is a novel receptor for the pyrazine derivatives. As shown in Figs. 1 and 2, ORSK1 responds to pyrazine derivatives represented by Formula (I) in dose dependent manner. Consequently, a substance which inhibits the response of OR5K1 causes a change in perception of the odor of pyrazine derivatives in the - 12 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780WO00) Specification of PCT Application central nervous system by masking based on the olfactory receptor antagonism and, as a result, can reduce the odor in an odor-specific manner. [0021] An aspect of the present invention provides an agent for reducing an odor of a pyrazine derivative, wherein the agent includes an antagonist of olfactory receptor OR5K1 for pyrazine derivatives as an active ingredient. Olfactory receptor OR5K1 is expressed in human olfactory cells and has been registered in GenBank under the accession number GI: 115270955. OR5K1 is a protein encoded by a gene having a nucleotide sequence represented by SEQ ID NO: 1 and having the amino acid sequence represented by SEQ ID NO: 2. [0022] "Pyrazine derivatives" in the present invention are compounds represented by the following Formula (I): R N rR1 N2 (I) In Formula (I), R 1 represents methyl, ethyl, or acetyl; and R 2 , R 3 , and R 4 each independently represent hydrogen or methyl. At least one of R 1 to R 4 is preferably an alkyl group, Examples of the pyrazine represented by Formula (I) of the present invention include 2,6-dimethylpyrazine, 2,5-dimethylpyrazine, 2,3 dimethylpyrazine, 2,3,5-trimethylpyrazine, 2,3,5,6 tetramethylpyrazine, 2-monomethylpyrazine, 2 - 13 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application monoethylpyrazine, 2-ethyl-6-methylpyrazine, 3-methyl-2 acetylpyrazine, and 3,5-dimethyl-2-acetylpyrazine. [0023] In the present invention, the "odor of a pyrazine derivative" can be an odor due to a pyrazine derivative represented by Formula (I). The "odor of a pyrazine derivative" in the present invention can be an odor generated by a Maillard reaction and is typically described as a roasted odor and the like. For example, Non-Patent Document 1 discloses that 2,6-dimethylpyrazine has "sweet, fried, resembling fried potatoes, nutty, roasted" odors. In addition, the "odor of a pyrazine derivative" in the present invention can be expressed as an odor generated in the use of a known self-tanning agent, more specifically, an earthy odor or an odor generated when dihydroxyacetone (DHA) or erythrulose reacts with the skin to change the color of skin to brown. [0024] The antagonist can block the response of olfactory receptor ORSK1 to a pyrazine derivative represented by Formula (I) by 40% or more, preferably 50% or more, and more preferably 75% or more, compared to the response in the absence of the antagonist. In other words, the response of olfactory receptor OR5Kl to the pyrazine derivative in the presence of the antagonist is reduced to 60% or less, preferably 50% or less, or more preferably 25% or less of the response of the receptor in the absence of the antagonist. - 14 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780WO00) Specification of PCT Application [0025] . Examples of the antagonist as an active ingredient of the agent for reducing an odor of a pyrazine derivative according to the present invention include the following substances: 2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2 buten-1-ol (bacdanol); 5-methyl-2-(1-methylethyl)-phenol (thymol); 3,7-dimethyl-2,6-octadienal (citral); phenylethyl salicylate; 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2 naphthalenyl)-ethanone (Tonalid (registered trademark), tentarome); isolongifolanone; 4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one (a-ionone); 4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-2-one (P-ionone); vetiverol; 7-acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7 tetramethyl-naphthalene (Iso E Super); a-amylcinnamic aldehyde; a-methyl-4-(1-methylethyl)-benzenepropanal (cyclamen aldehyde); 4-methyl-3-decen-5-ol (undecavertol); 1-(2-tert-butylcyclohexyloxy)-2-butanol (Amber Core (registered trademark)); - 15 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application 2-methoxy-1-(phenylmethoxy)-4-(1-propenyl)-benzene (benzyl isoeugenol); a-methyl-$-(p-tert-butylphenyl)-propionaldehyde (lilial); 1 (-) -menthol; o-6-hexadecenelactone (ambrettolide); 2-(2-(4-methyl)-3-cyclohexen-1-yl) propylcyclopentanone (nectaryl); formaldehyde cyclododecyl ethyl acetal (Boisambrene Forte (registered trademark)); 1-(2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-lH 3a,7-methanoazulen-5-yl)-ethanone (acetyl cedrene); -methyl naphthyl ketone; cedryl acetate; (5E)-3-methylcyclopenta-5-decen-l-one (8-muscenone); cinnamaldehyde; 4-(1-ethoxyvinyl)-3,3,5,5-tetramethylcyclohexanone (kephalis); ax-hexylcinnamic aldehyde; 2-phenylpropionaldehyde (hydratropic aldehyde); 3,7-dimethyl-6-octenal (citronellal); dodecahydro-3a,6,6,9a-tetramethylnaphtho[2,1-b]furan (Ambrotech (registered trademark)); 4,7,7-trimethyl-spirobicyclo[2.2.1]heptane-2,1 cyclopentan-3-one (Sagetone (registered trademark) V); a-isomethyl ionone (y-methyl ionone); 3,7-dimethyl-1-octanol (tetrahydrogeraniol); cedryl methyl ether; - 16 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application muscone; 2-methyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2 buten-1-ol (Sandalmysore Core (registered trademark)); 2-cyclohexylpropanal (Pollenal (registered trademark) II); y-undecalactone; cyclopentadecanolide (pentalide); 1-(2,6,6-trimethyl-1,3-cyclohexadien-1-yl)-2-buten 1-one (damascenone); 2,4-dimethyl-3-cyclohexene-l-carboxyaldehyde -(triplal); 2,4,6-trimethyl-3-cyclohexene-1-carboxyaldehyde or 3,5,6-trimethyl-3-cyclohexene-1-carboxyaldehyde (isocyclocitral); 6,10-dimethyl-3-oxa-9-undecenal (citronellyloxyacetaldehyde); dimethyl benzyl carbinyl acetate; ethyl-(3aa,4a,7a,3aa)-octahydro-4,7-methano-3aH indene-3a-carboxylate (Fruitate (registered trademark)); 2-pentyl-3-methyl-2-cyclopenten-1-one (dihydrojasmon); phenylhexanol; 1-(5,5-dimethyl-1-cyclohexen-1-yl)-4-penten-l-one (Dynascone (registered trademark)); 6-tert-butyl-1,1-dimethylinden-4-yl methyl ketone (celestolide); cis-4-isopropylcyclohexylmethanol (mayol); 1-allyl-3-methoxy-4-hydroxybenzene (eugenol); - 17 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application (E)-3,7-dimethyl-2,6-octadien-l-ol (geraniol); 4-tert-butyl-2,6-dimethyl-3,5-dinitroacetophenone (musk ketone); 1,4-dioxacycloheptadecane-5,17-dione (ethylene brassylate); hexyl salicylate; and a-methyl-3,4-methylenedioxyhydrocinnamic aldehyde (helional). [0026] Among the above-mentioned antagonists, preferred examples as the active ingredient of the agent for reducing an odor of a pyrazine derivative according to the present invention include 2-ethyl-4-(2,2,3-trimethyl 3-cyclopenten-1-yl)-2-buten-l-ol (bacdanol); 5-methyl-2 (1-methylethyl)-phenol (thymol); 3,7-dimethyl-2,6 octadienal (citral); phenylethyl salicylate; 1-(5,6,7,8 tetrahydro-3,5,5,6,8,8-hexamethyl-2-naphthalenyl) ethanone (Tonalid (registered trademark), tentarome); isolongifolanone; 4-(2,6,6-trimethyl-2-cyclohexen-1-yl) 3-buten-2-one (a-ionone); 4-(2,6,6-trimethyl-l cyclohexen-1-yl)-3-buten-2-one (-ionone); vetiverol; 7 acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7-tetramethyl naphthalene (Iso E Super); a-amylcinnamic aldehyde; a methyl-4-(1-methylethyl)-benzenepropanal (cyclamen aldehyde); 4-methyl-3-decen-5-ol (undecavertol); and 1 (2-tert-butylcyclohexyloxy)-2-butanol (Amber Core (registered trademark)). [0027] - 18 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application As the active ingredient of the agent for reducing an odor of a pyrazine derivative according to the present invention may be at least one selected from the above mentioned antagonists. That is, the above-mentioned antagonists are contained in the agent for reducing an odor of a pyrazine derivative of the present invention alone or in a combination of two or more thereof. Preferably, the agent for reducing an odor of a pyrazine derivative of the present invention is essentially composed of any one of the above-mentioned antagonists or a combination of two or more of the above-mentioned antagonists. [0028] As shown in Table 4, these substances are antagonists of olfactory receptor OR5K1 and inhibit the response of the olfactory receptor to pyrazine derivatives represented by Formula (I). The substances have been known as flavoring raw materials, but have not been known to have a function of blocking response of an olfactory receptor to pyrazine derivatives and thereby reducing the odors of the pyrazine derivatives. [0029] The above-mentioned antagonists are commercially available (see "Gosei Koryo (Synthetic Flavoring Materials): Kagaku to Syohin Chishiki (Chemistry and Knowledge on Products)", enlarged and revised edition, by Genichi Indo, The Chemical Daily Co., Ltd., published in March, 2005) . For example, they are available from - 19 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application Firmenich S.A., Givaudan S.A., International Flavors & Fragrances Inc., Takasago International Corporation, and Kao Corporation. [0030] In another aspect of the present invention, the above-mentioned antagonists of olfactory receptor ORSK1 can be contained in compounds or compositions for reducing the odor of pyrazine derivatives as active ingredients for reducing the odors of the pyrazine derivatives. Alternatively, the antagonists can be used for producing agents for reducing odors of pyrazine derivatives or for producing compounds or compositions for reducing the odor of pyrazine derivatives. [0031] The agent, the compound, or the composition for reducing the odor of a pyrazine derivatives described above may contain, in addition to the substance of the present invention, another component having a malodor reducing effect or an appropriate component used in a deodorant or a deodorizer. For example, a flavoring agent, a powder component, a liquid oil or fat, a solid oil or fat, a wax, a hydrocarbon, a plant extract, a Chinese medicine component, a higher alcohol, a lower alcohol, an ester, a long-chain fatty acid, a surfactant (e.g., nonionic surfactant, anionic surfactant, cationic surfactant, or ampholytic surfactant), a sterol, a polyol, a moisturizer, a water-soluble high-molecular-weight compound, a thickener, a film-forming agent, a sterilizer, - 20 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application a preservative, an anti-fungal agent, a ultraviolet absorber, a fixing agent, a cold-sensing agent, a warm sensing agent, a stimulant, a sequestering agent, sugar, an amino acid, an organic amine, a synthetic resin emulsion, a pH adjuster, an antioxidant, an antioxidant auxiliary, an oil, a powder, a capsule, a chelating agent, an inorganic salt, an organic salt dye, a colorant, an antifoaming agent, a bulking agent, a modulator, an organic acid, a polymer, a polymer-dispersing agent, an enzyme, or an enzyme stabilizer may be appropriately contained according to the object. [0032] The another component having a malodor reducing effect which can be contained in the agent, the compound, or the composition for reducing an odor of a pyrazine derivative may be any known deodorant having a chemically or physically malodor reducing effect. Examples of the component include malodor reducing active ingredients extracted from each part of plants, such as a leaf, a leafstalk, a seed, a stalk, a root, and a bark (e.g., green tea extract); organic acids such as lactic acid, gluconic acid, succinic acid, glutanic acid, adipic acid, malic acid, tartaric acid, maleic acid, fumaric acid, itaconic acid, citric acid, benzoic acid, and salicylic acid; various amino acids and salts thereof; glyoxal, oxidizing agents, flavonoids, catechins, and polyphenols; porous materials such as activated carbon and zeolite; - 21 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application inclusion agents such as cyclodextrins; photocatalysts; and various masking agents. [0033] In another aspect of the present invention, the above-mentioned antagonists of olfactory receptor OR5K1 can be used as active ingredients for reducing odors of pyrazine derivatives in every compound or composition desired to reduce the odor of the pyrazine derivatives or under every environment desired to reduce the odor of the pyrazine derivatives. Alternatively, the antagonists can be used for producing compounds or compositions desired to reduce the odor of pyrazine derivatives as active ingredients for reducing the odors of the pyrazine derivatives. Examples of the compounds or the compositions desired to reduce the odor of the pyrazine derivatives include skin tanning agents (also called self-tanning agent or sunless tanning agent), for example, a skin tanning agent containing dihydroxyacetone (DHA) or erythrulose as a color former and another skin tanning agent utilizing a browning reaction. The pyrazine derivatives may be contained in foods as flavoring components and may cause off-flavors if their amounts are high. Accordingly, other examples of the compounds or the compositions desired to reduce the odor of the pyrazine derivatives include foods containing the pyrazine derivatives as flavoring components and compositions thereof, more specifically, foods, such as roasted peanuts and milk powders, of which taste is - 22 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application reduced by the presence of'excess amounts of pyrazine derivatives and compositions thereof. [0034] As further another aspect, the present invention provides a method of reducing an odor of a pyrazine derivative. The method includes a step of allowing an odor of a pyrazine derivative and an antagonist of olfactory receptor OR5K1 to coexist. In the method, an antagonist of olfactory receptor ORSK1 is applied, in the presence of the odor of pyrazine derivatives, to an individual desiring to inhibit perception of the odor, preferably, an individual desiring to inhibit perception of the odor of pyrazine derivatives through masking by the olfactory receptor antagonism, and thereby the odor of pyrazine derivatives and the antagonist are allowed to coexist. Consequently, the antagonist binds to OR5K1 to inhibit the response of OR5K1, and thereby masking by the olfactory receptor antagonism occurs to reduce the odor of pyrazine derivatives. Preferred antagonists in the method of the present invention are similar to the above-described agents for reducing the odor of the pyrazine derivatives. [0035] In the method of the present invention, the individual is not particularly limited but may be any mammal and is preferably human, Examples of the individual desiring to inhibit perception of an odor of a pyrazine derivative in the method of the present - 23 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780WO00) Specification of PCT Application invention include human using a skin tanning agent (or self-tanning agent or sunless tanning agent), more specifically, a skin tanning agent containing dihydroxyacetone (DHA) or erythrulose as a color former or another skin tanning agent utilizing a browning reaction and human desiring to reduce an odor of a pyrazine derivative from a food, for example, human ingesting a food, such as a roasted peanut or a milk powder, of which taste is reduced by the presence of an excess amount of the pyrazine derivative. [0036] In an embodiment of the above-described aspect, the antagonist of olfactory receptor OR5K1 is blended with a compound or a composition containing a pyrazine derivative. By doing so, the response of an olfactory receptor to the pyrazine derivative contained in the compound or the composition is reduced to inhibit the perception of the pyrazine derivative odor by the individual, resulting in reduction of the odor. In another embodiment, the antagonist of olfactory receptor OR5K1 is blended with a compound or a composition which may generate a pyrazine derivative. By doing so, the response of the olfactory receptor to the pyrazine derivative generated by the compound or the composition is reduced to inhibit the perception of the pyrazine derivative odor by the individual, resulting in reduction of the odor. Examples of the compound or the composition which may generate a pyrazine derivative - 24 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application include skin tanning agents, for example, a skin tanning agent containing dihydroxyacetone (DHA) or erythrulose as a color former and another skin tanning agent utilizing a browning reaction. [0037] The following compositions, production methods, usages or methods are further disclosed herein as another embodiment of the present invention, that are, however, not intended to limit the scope of the present invention. [0038] <1> Use of at least one compound selected from the group consisting of compounds described in Table 1 above, as an antagonist of olfactory receptor OR5K1. [0039] <2> Use of at least one compound selected from the group consisting of compounds described in Table 1 above, for reducing an odor of a pyrazine derivative. [0040] <3> Use of at least one compound selected from the group consisting of compounds described in Table 1 above, for producing an agent for reducing an odor of a pyrazine derivative. [0041] <4> Use of at least one compound selected from the group consisting of compounds described in Table 1 above, for producing a skin tanning agent. [0042] - 25 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application <5> A method of reducing an odor of a pyrazine derivative, wherein the method includes coexisting an odor of a pyrazine derivative with at least one compound selected from the group consisting of compounds described in Table 1 above. [0043] <6> The method according to <5>, which includes applying the at least one compound to an individual in need of reduction of odor of the pyrazine derivative in the presence of the odor of the pyrazine derivative. [0044] <7> The method according to <6>, wherein the at least one compound inhibits responses of an olfactory receptor OR5K1. [0045] <8> A method of antagonizing responses of an olfactory receptor OR5K1, wherein the method includes applying, to an olfactory receptor ORSK1, at least one compound selected from the group consisting of compounds described in Table 1 above. [0046] <9> In any of <2> to <8>, the pyrazine derivative may be a compound represented by the following formula (I):
    R
    4 , N R 1
    R
    3 N R2 () - 26 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application wherein R, represents methyl, ethyl or acetyl; and R 2 ,
    R
    3 and R 4 each independently represent hydrogen or methyl. [0047] <10> In <9>, at least one of R, to R 4 may represents an alkyl group. [0048] <11> In any of <2> to <10>, the pyrazine derivatives may be selected from the group consisting of 2,6 dimethylpyrazine, 2,5-dimethylpyrazine, 2,3 dimethylpyrazine, 2,3,5-trimethylpyrazine, 2,3,5,6 tetramethylpyrazine, 2-monomethylpyrazine, 2 monoethylpyrazine, 2-ethyl-6-methylpyrazine, 3-methyl-2 acetylpyrazine and 3,5-dimethyl-2-acetylpyrazine. [0049] <12> In any of <2> to <11>, the at least one compound may be selected from the group consisting of compounds described in Table 2 below. [00501 - 27 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application [Table 2] 2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2-buten 1-ol 5-methyl-2-(1-methylethyl)-phenol 3,7-dimethyl-2,6-octadienal phenylethyl salicylate 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2 naphthalenyl)-ethanone isolongifolanone 4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one
    (CC
    ionone) 4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-2-one
    ($
    ionone) vetiverol 7-acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7-tetramethyl naphthalene a-amylcinnamic aldehyde a-methyl-4-(1-methylethyl)-benzenepropanal 4-methyl-3-decen-5-ol 1-(2-tert-butylcyclohexyloxy)-2-butanol [0051] <13> In any of <2> to <12>, the odor of the pyrazine derivative may be an odor generated by reaction of a skin tanning agent with skin. [00521 <14> In <1>, at least one compound is preferably selected from the group consisting of compounds described below: - 28 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application 2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2 buten-1-ol 3,7-dimethyl-2,6-octadienal phenylethyl salicylate 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2 naphthalenyl)-ethanone Isolongifolanone Vetiverol 7-acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7 tetramethyl-naphthalene a-amylcinnamic aldehyde a-methyl-4-(1-methylethyl)-benzenepropanal 4-methyl-3-decen-5-ol 2-methoxy-l-(phenylmethoxy)-4-(1-propenyl)-benzene a-methyl-5-(p-tert-butylphenyl)-propionaldehyde 1 (-) -menthol o-6-hexadecenelactone 2-(2-(4-methyl)-3-cyclohexen-1-yl) propylcyclopentanone formaldehyde cyclododecyl ethyl acetal -methyl naphthyl ketone cedryl acetate (5E)-3-methylcyclopenta-5-decen-l-one cinnamaldehyde 4-(1-ethoxyvinyl)-3,3,5,5-tetramethylcyclohexanone a-hexylcinnamic aldehyde 2-phenylpropionaldehyde - 29 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application 4,7,7-trimethyl-spirobicyclo[2.2.1]heptane-2,1 cyclopentan-3-one cedryl methyl ether muscone 2-methyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2 buten-1-ol 1-(2,6,6-trimethyl-1,3-cyclohexadien-1-yl)-2-buten 1-one 2,4-dimethyl-3-cyclohexene-l-carboxyaldehyde 2,4,6-trimethyl-3-cyclohexene-l-carboxyaldehyde 3,5,6-trimethyl-3-cyclohexene-l-carboxyaldehyde 6,10-dimethyl-3-oxa-9-undecenal dimethyl benzyl carbinyl acetate ethyl-(3aa,4a,7c',3aa)-octahydro-4,7-methano-3aH indene-3a-carboxylate 2-pentyl-3-methyl-2-cyclopenten-1-one Phenylhexanol 6-tert-butyl-1,1-dimethylinden-4-yl methyl ketone cis-4-isopropylcyclohexylmethanol 1-allyl-3-methoxy-4-hydroxybenzene 4-tert-butyl-2,6-dimethyl-3,5-dinitroacetophenone 1,4-dioxacycloheptadecane-5,17-dione hexyl salicylate ac-methyl-3,4-methylenedioxyhydrocinnamic aldehyde [0053] <15> In <1>, at least one compound is more preferably selected from the group consisting of compounds described below: - 30 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application 2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2 buten-1-ol; 3,7-dimethyl-2,6-octadienal; phenylethyl salicylate; 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2 naphthalenyl)-ethanone; isolongifolanone; vetiverol; 7-acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7 tetramethyl-naphthalene; c-amylcinnamic aldehyde; a-methyl-4-(1-methylethyl)-benzenepropanal; 4-methyl-3-decen-5-ol. Examples [0054] The present invention will now be described more specifically by examples. [0055] Example 1 Identification of olfactory receptor responding to pyrazine derivative 1) Cloning of human olfactory receptor gene Human olfactory receptors were cloned based on sequence information registered in GenBank by PCR using human genomic DNA female (G1521: Promega Corporation) as a template. Each gene amplified by PCR was inserted into a pENTR vector (Invitrogen Inc.) in accordance with the manual and was recombined into the NotI and AscI site - 31 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application located downstream of a Flag-Rho tag sequence in a pME18S vector using the NotI and AscI site present in the pENTR vector. [0056] 2) Production of pME18S-RTP1S vector An RTP1S variant gene (SEQ ID NO: 3) encoding an RTP1S variant (SEQ ID NO: 4) was inserted into the EcoRI and XhoI site of a pME18S vector. [00571 3) Production of olfactory receptor-expressing cell HEK293 cells expressing 373 types of human olfactory receptors were produced. A reaction solution having a composition shown in Table 1 was prepared and left to stand in a clean bench for 15 min and then was dispensed in each well of a 96-well plate (Becton, Dickinson and Company) . Subsequently, HEK293 cells (100 pL, 3 x 105 cells/cm 2 ) were seeded in each well and cultured in an incubator at 37 0 C and 5% CO 2 for 24 hr. [0058] [Table 3) OPTI-MEM (GIBCO) 50 pL Human olfactory receptor gene 0.075 ptg (incorporated in a pME18S vector having a Flag-Rho tag at the N-terminal) pGL4.29 (fluc2P-CRE-hygro, Promega Corp.) 0.03 pg pGL4.75 (hRluc-CMV, Promega Corp.) 0.03 ptg pME18S-RTP1S variant vector 0.03 pg Lipofectamine 2000 (Invitrogen Inc.) 0.4 pl [0059] 4) Luciferase assay - 32 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application An olfactory receptor expressed in HEK293 cells couples with endogenous Gas in the cells to activate adenylate cyclase and thereby increases the amount of intracellular cAMP. In this study, the response of a pyrazine derivative was measured by luciferase reporter gene assay which monitors an increase in amount of intracellular cAMP as the luminescence value derived from a firefly luciferase gene (fluc2P-CRE-hygro) . A Renilla luciferase gene was fused downstream of a CMV promoter (hRluc-CMV) and was also introduced to HEK293 cells as an internal standard to correct errors in transgenic efficiency and number of cells. The culture medium was removed from the culture produced in the above 3), and 75 pL of a solution prepared with a CD293 medium (Invitrogen Inc.) so as to contain a pyrazine derivative (1 mM, 2,6 dimethylpyrazine) was added thereto. The cells were cultured in a CO 2 incubator for 2.5 hr to sufficiently express the luciferase gene in the cells. The luciferase activity was measured with a Dual-Glo"T luciferase assay system (Promega Corporation) in accordance with the operating manual of the system. The fold increases were calculated by dividing the luminescence value derived from firefly luciferase induced by stimulation with a pyrazine derivative at each concentration by the luminescence value in cells not stimulated with the pyrazine derivative and were used as an index of response strength. - 33 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780WO00) Specification of PCT Application [0060] 5) Results The response of each of the 373 types of the olfactory receptors to 2,6-dimethylpyrazine (1 mM) was measured, and the result showed that only olfactory receptor OR5K1 responded to 2,6-dimethylpyrazine (Fig. 1). Response of OR5K1 to 2,6-dimethylpyrazine has not been reported until now, and OR5K1 is a novel 2,6 dimethylpyrazine receptor. [0061] Example 2 Response characteristics of ORSK1 to pyrazine derivatives Olfactory receptor OR5K1 (SEQ ID NO: 2) was expressed in HEK293 cells together with an RTP1S variant (SEQ ID NO: 4) by the same procedure as in Example 1, and the dependency of the response on the concentration (0, 3, 10, 30, 100, 300, and 1000 pM) of various pyrazine compounds was investigated. The pyrazine compounds used in this Example were pyrazine and pyrazine derivatives selected from the group consisting of 2-methylpyrazine, 2,3-dimethylpyrazine, 2,5-dimethylpyrazine, 2,3,5 trimethylpyrazine, 2,3,5,6-tetramethylpyrazine, and 2 ethylpyrazine. The results showed that OR5K1 dose-dependently responded to the pyrazine derivatives, i.e., 2 methylpyrazine (2-MMP), 2,3-dimethylpyrazine (2,3-DMP), 2,5-dimethylpyrazine (2,5-DMP), 2,6-dimethylpyrazine (2,6-DMP), 2,3,5-trimethylpyrazine (2,3,5-TMP), 2,3,5,6 - 34 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application tetramethylpyrazine (2,3,5,6-TMP), and 2-ethylpyrazine (2-MEP), but did not respond to pyrazine (Fig. 2). [0062] Example 3 Identification of antagonist of OR5K1 Antagonistic activities of 174 test substances against olfactory receptor OR5K1 were investigated by examining response of OR5K1 to a pyrazine derivative. 2,6-Dimethylpyrazine (1 mM) and each test substance (300 ILM) shown in Table 4 were added to HEK293 cells expressing olfactory receptor OR5K1 by the same procedure as in Example 2, and the response of the olfactory receptor to 2,6-dimethylpyrazine was measured to evaluate a change in response of the receptor due to addition of the test substance, Flavoring agents recognized to have cytotoxicity were re-evaluated using a mixture of 333 pM of 2,6-dimethylpyrazine and 100 pM of a test substance. The receptor response-inhibiting rate of a test substance was calculated as follows. The receptor activity (X-Y) by stimulation with 2,6-dimethylpyrazine alone was determined by subtracting the luminescence value (Y) in cells to which the receptor was introduced but were not stimulated with 2,6-dimethylpyrazine from the luminescence value (X) derived from firefly luciferase induced by stimulation with 2,6 dimethylpyrazine alone. Similarly, the receptor activity (Z-Y) in the presence of a test substance was determined by subtracting the luminescence value (Y) in cells not stimulated with 2,6-dimethylpyrazine from the - 35 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application luminescence value (Z) stimulated with a mixture of 2,6 dimethylpyrazine and the test substance. The reduction rate of the receptor activity (Z-Y) in the presence of a test substance to the receptor activity (X-Y) by stimulation with 2,6-dimethylpyrazine alone was calculated by the following computation expression: Inhibition rate (%) = {1-(Z-Y)/(X-Y)) x 100, to determine the receptor response-inhibiting rate of the test substance. In the measurement, multiple independent experiments were performed in duplicate, and the average of each experiment was used. As shown in Table 4, the results showed that 56 test substances had antagonistic activity on the response of OR5K1 to 2,6-dimethylpyrazine. [00631 - 36 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application [Table 4] Inhibition rate: Inhibition rate: 50% Inhibition rate: 75% or more or more 40% or more (exceptionally- (strong antagonist) (weak antagonist) strong antagonist) 2-ethyl-4- 2-methoxy-1- cyclo (2,2,3- (phenylmethoxy)-4- pentadecanolide trimethyl-3- (1-propenyl) -benzene (pentalide) cyclopenten-1- (benzyl isoeugenol) yl) -2-buten-1-ol 1-.(2, 6, 6 (bacdanol) a-methyl-p-(p-tert- trimethyl-1,3 butylphenyl)- cyclohexadien-l 5-methyl-2-(1- propionaldehyde yl)-2-buten-1 methylethyl)- (lilial) one(damascenone) phenol (thymol) 1(-)-menthol 2,4-dimethyl-3 3,7-dimethyl- cyclohexene-1 2,6-octadienal o-6_ carboxyaldehyde (citral) hexadecenelactone (triplal) phenylethyl (ambrettolide) isocyclocitral salicylate 2- (2- (4-methyl) -3 cyclohexen-1-yl)- 6,10-dimethyl-3 1-(5,6,7,8- propylcyclopentanone oxa-9-undecenal tetrahydro- (nectaryl) (citronellyl 3,5,5,6,8,8- oxyacetaldehyde) hexamethyl-2- formaldehyde naphthalenyl)- cyclododecyl ethyl dimethyl benzyl ethanone acetal (Boisambrene carbinyl acetate (Tonalid Forte (registered (registered trademark)) ethyl trademark), (3a,4a,7c,3a.) tentarome) 1-(2,3,4,7,8,8a- octahydro-4,7 hexahydro-3,6,8,8- methano-3aH Isolongifolanone tetramethyl-1H-3a,7- indene-3a methanoazulen-5-yl)- carboxylate 4-(2,6,6~ ethanone (acetyl (Fruitate trimethyl-2- cedrene) (registered cyclohexen-1- trademark)) yl)-3-buten-2- P-methyl naphthyl one (a-ionone) ketone - 37 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application Table 4(cont'd 1) Inhibition rate: 75% Inhibition rate: Inhibition rate: or more 50% or more 40% or more (exceptionally- (strong (weak strong antagonist) antagonist) antagonist) 4-(2,6,6-trimethyl- cedryl acetate 2-pentyl-3 1-cyclohexen-1-yl)- methyl-2 3-buten-2-one (5- (5E)-3- cyclopenten-1 ionone) methylcyclopenta- one 5-decen-l-one (8- (dihydrojasmon) vetiverol muscenone) phenylhexanol 7-acetyl- cinnamaldehyde 1-(5,5-dimethyl 1,2,3,4,5,6,7,8- 1-cyclohexen-1 octahydro-1,1,6,7- 4-(1- yl)-4-penten-1 tetramethyl- ethoxyvinyl)- one (Dynascone naphthalene (Iso E 3,3,5,5- (registered Super) tetramethyl- trademark)) cyclohexanone ca-amylcinnamic (kephalis) 6-tert-butyl aldehyde 1,1 a-hexylcinnamic dimethylinden-4 a-methyl-4-(1- aldehyde (l methyl ketone methylethyl)- (celestolide) benzenepropanal 2 (cyclamen aldehyde) phenylpropional- cis-4-isopropyl dehyde cyclohexyl 4-methyl-3-decen-5- (hydratropic methanol (mayol) ol (undecavertol) aldehyde) 1-allyl-3 1-(2-tert- 3,7-dimethyl-6- methoxy-4 butylcyclohexyloxy) - octenal hydroxybefzene 2-butanol (Amber (citronellal) (eugenol) Core (registered trademark)) dodecahydro- (E)-3,.7 3a,6,6,9a- dimethyl-2,6 tetramethyl- octadien-1-ol naphtho (geraniol) [2,1-b]furan (Ambrotech (registered trademark)) - 38 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application Table 4 (cont'd 2) Inhibition rate: Inhibition rate: 50% Inhibition rate: 75% or more or more 40% or more (exceptionally- (strong antagonist) (weak antagonist) strong antagonist) 4,7,7-trimethyl- 4-tert-butyl-2,6 spirobicyclo [2.2.1] dimethyl-3, 5 heptane-2,1- dinitro cyclopentan-3-one acetophenone (Sagetone (musk ketone) (registered trademark) V) 1,4-dioxacyclo heptadecane-5,17 a-isomethyl ionone dione (ethylene (y-methyl ionone) brassylate) 3,7-dimethyl-l- hexyl salicylate octanol (tetrahydrogeraniol) a-methyl-3, 4 methylenedioxy cedryl methyl ether hydrocinnamic aldehyde muscone (helional) 2-methyl-4- (2,2,3 trimethyl-3 cyclopenten-1-yl)-2 buten-1-ol (Sandalmysore Core (registered trademark)) 2-cyclohexylpropanal (Pollenal (registered trademark) II) y-undecalactone - 39 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application [0064] Example 4 Evaluation of ability of antagonist of OR5K1 for reducing odors of pyrazine derivatives The abilities to reduce an odor of a pyrazine derivative by the antagonist substances identified in Example 3 were confirmed by a sensory test. A flavoring agent (0.5 ptL) was added to cloth (0.5 g) containing 2,6-dimethylpyrazine (1%), and the odor thereof was evaluated by comparing the strength of odor of 2,6-dimethylpyrazine of the cloth not applied with flavor by the flavoring agent. The sensory evaluation test was performed by four panelists. In the evaluation, a case where a strong odor of 2,6-dimethylpyrazine was smelled was rated as 1, and a case where the odor of 2,6 dimethylpyrazine was not smelled at all was rated as 5. As a result, the odor of 2,6-dimethylpyrazine was inhibited by the antagonists which were revealed in Example 3 to inhibit the response of OR5K1 to 2,6 dimethylpyrazine, that is, the odor of 2,6 dimethylpyrazine was inhibited by 4-(2,6,6-trimethyl-l cyclohexen-1-yl)-3-buten-2-one (P-ionone), 4-methyl-3 decen-5-ol (undecavertol), 1-(2-tert-butylcyclohexyloxy) 2-butanol (Amber Core (registered trademark)), a-methyl f-(p-tert-butylphenyl)-propionaldehyde (lilial), P-methyl naphthyl ketone, (5E)-3-methylcyclopenta-5-decen-l-one (-muscenone), a-hexylcinnamic aldehyde, a-isomethyl ionone (y-methyl ionone) , 2-methyl-4- (2,2,3-trimethyl-3 cyclopenten-1-yl)-2-buten-l-ol (Sandalmysore Core - 40 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application (registered trademark)), y-undecalactone, 1- (2,6,6 trimethyl-1,3-cyclohexadien-1-yl)-2-buten-l-one (damascenone), 2,4-dimethyl-3-cyclohexene-l carboxyaldehyde (triplal), ethyl-(3ax,4a,7ci,3aa) octahydro-4,7-methano-3aH-indene-3a-carboxylate (Fruitate (registered trademark)), 1-(5,5-dimethyl-l-cyclohexen-l yl)-4-penten-l-one (Dynascone (registered trademark)), (E)-3,7-dimethyl-2,6-octadien-l-ol (geraniol), and a methyl-3,4-methylenedioxyhydrocinnamic aldehyde (helional) (Fig. 3). [0065] The embodiments of the present invention have been described above, but it should be understood that the specific embodiments described above are not intended to limit the present invention. Various other changes and modifications within the scope of the present invention are obvious to those skilled in the art. The documents and patent applications cited in this specification are incorporated by reference herein in their entirety. - 41 -
    权利要求:
    Claims (19)
    [1] 1. Use of at least one compound selected from the group consisting of the following compounds for reducing an odor of a pyrazine derivative:
    [2] 2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2- buten-1-ol;
    [3] 5-methyl-2-(1-methylethyl)-phenol; 3,7-dimethyl-2,6-octadienal; phenylethyl salicylate; 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2 naphthalenyl)-ethanone; isolongifolanone; 4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one (w-ionone); 4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-2-one (0-ionone); vetiverol;
    [4] 7-acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7 tetramethyl-naphthalene; a-amylcinnamic aldehyde; x-methyl-4-(1-methylethyl)-benzenepropanal; 4-methyl-3-decen-5-ol; 1-(2-tert-butylcyclohexyloxy)-2-butanol; 2-methoxy-l-(phenylmethoxy)-4-(1-propenyl)-benzene; a-methyl-p-(p-tert-butylphenyl)-propionaldehyde; 1(-)-menthol; o-6-hexadecenelactone; - 42 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application 2-(2-(4-methyl)-3-cyclohexen-1-yl) propylcyclopentanone; formaldehyde cyclododecyl ethyl acetal; 1-(2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-lH 3a,7-methanoazulen-5-yl)-ethanone; P-methyl naphthyl ketone; cedryl acetate; (SE)-3-methylcyclopenta-5-decen-l-one; cinnamaldehyde; 4-(l-ethoxyvinyl)-3,3,5,5-tetramethylcyclohexanone; c-hexylcinnamic aldehyde; 2-phenylpropionaldehyde; 3,7-dimethyl-6-octenal; dodecahydro-3a,6,6,9a-tetramethylnaphtho[2,1 b]furan; 4,7,7-trimethyl-spirobicyclo[2.2.1]heptane-2,1 cyclopentan-3-one; a-isomethyl ionone; 3,7-dimethyl-l-octanol; cedryl methyl ether; muscone; 2-methyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2 buten-l-ol; 2-cyclohexylpropanal; y-undecalactone; cyclopentadecanolide; 1-(2,6,6-trimethyl-1,3-cyclohexadien-1-yl)-2-buten 1-one; - 43 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application 2,4-dimethyl-3-cyclohexene-1-carboxyaldehyde; 2,4,6-trimethyl-3-cyclohexene-l-carboxyaldehyde; 3,5,6-trimethyl-3-cyclohexene-1-carboxyaldehyde; 6,10-dimethyl-3-oxa-9-undecenal; dimethyl benzyl carbinyl acetate; ethyl-(3aax,4a,7a,3aa)-octahydro-4,7-methano-3aH indene-3a-carboxylate; 2-pentyl-3-methyl-2-cyclopenten-l-one; phenylhexanol; 1-(5,5-dimethyl-1-cyclohexen-1-yl)-4-penten-l-one; 6-tert-butyl-1,1-dimethylinden-4-yl methyl ketone; cis-4-isopropylcyclohexylmethanol; 1-allyl-3-methoxy-4-hydroxybenzene; (E)-3,7-dimethyl-2,6-octadien-l-ol; 4-tert-butyl-2,6-dimethyl-3,5-dinitroacetophenone; 1,4-dioxacycloheptadecane-5,17-dione; hexyl salicylate; and a-methyl-3,4-methylenedioxyhydrocinnamic aldehyde. 2. The use according to Claim 1, wherein the pyrazine derivative is a compound represented by the following Formula (I): R4 N R1 R N R 2 wherein R 1 represents methyl, ethyl, or acetyl; and R 2 , R 3 , and R 4 each independently represent hydrogen or methyl. - 44 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application 3. The use according to Claim 2, wherein at least one of R, to R 4 represents an alkyl group. 4. The use according to any one of Claims 1 to 3, wherein the pyrazine derivative is selected from the group consisting of 2,6-dimethylpyrazine, 2,5 dimethylpyrazine, 2,3-dimethylpyrazine, 2,3,5 trimethylpyrazine, 2,3,5,6-tetramethylpyrazine, 2 monomethylpyrazine, 2-monoethylpyrazine, 2-ethyl-6 methylpyrazine, 3-methyl-2-acetylpyrazine, and 3,5 dimethyl-2-acetylpyrazine. 5. The use according to any one of Claims 1 to 4, wherein the at least one compound is selected from the group consisting of the following compounds: 2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2 buten-1-ol; 5-methyl-2-(1-methylethyl)-phenol; 3,7-dimethyl-2,6-octadienal; phenylethyl salicylate; 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2 naphthalenyl)-ethanone; isolongifolanone; 4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one (a-ionone); 4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-2-one (j-ionone); vetiverol; - 45 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application 7-acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7 tetramethyl-naphthalene; a-amylcinnamic aldehyde; a-methyl-4-(1-methylethyl)-benzenepropanal; 4-methyl-3-decen-5-ol; and 1-(2-tert-butylcyclohexyloxy)-2-butanol. 6. The use according to any one of Claims 1 to 5, wherein the odor of the pyrazine derivative is an odor generated by reaction of a skin tanning agent with skin. 7. The use according to any one of claims 1 to 6, wherein the at least one compound is an antagonist of an olfactory receptor OR5K1.
    [5] 8. A method of reducing an odor of a pyrazine derivative, wherein the method comprises coexisting an odor of a pyrazine derivative with at least one compound selected from the group consisting of the following compounds: 2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2 buten-1-ol; 5-methyl-2-(1-methylethyl)-phenol; - 3, 7-dimethyl-2, 6-octadienal; phenylethyl salicylate; 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2 naphthalenyl)-ethanone; isolongifolanone; - 46 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application 4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten- 2 -one (a-ionone); 4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten- 2 -one ($-ionone); vetiverol; 7-acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7 tetramethyl-naphthalene; a-amylcinnamic aldehyde; cx-methyl-4-(1-methylethyl)-benzenepropanal; 4-methyl-3-decen-5-ol; 1--(2-tert-butylcyclohexyloxy)-2-butanol; 2-methoxy-l-(phenylmethoxy)-4-(1-propenyl)-benzene; a-methyl-p-(p-tert-butylphenyl)-propionaldehyde; 1(-)-menthol; o-6-hexadecenelactone; 2-(2-(4-methyl)-3-cyclohexen-1-yl) propylcyclopentanone; formaldehyde cyclododecyl ethyl acetal; 1-(2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-1H 3a,7-methanoazulen-5-yl)-ethanone; P-methyl naphthyl ketone; cedryl acetate; (SE)-3-methylcyclopenta-5-decen-l-one; cinnamaldehyde; 4-(1-ethoxyvinyl)-3,3,5,5-tetramethylcyclohexanone; c-hexylcinnamic aldehyde; 2-phenylpropionaldehyde; 3,7-dimethyl-6-octenal; - 47 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application dodecahydro-3a,6,6,9a-tetramethylnaphtho[2,1 bifuran; 4,7,7-trimethyl-spirobicyclo[2.2.1]heptane-2,1 cyclopentan-3-one; ca-isomethyl ionone; 3,7-dimethyl-l-octanol; cedryl methyl ether; muscone; 2-methyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2 buten-l-ol; 2-cyclohexylpropanal; y-undecalactone; cyclopentadecanolide; 1-(2,6,6-trimethyl-1,3-cyclohexadien-1-yl)-2-buten 1-one; 2,4-dimethyl-3-cyclohexene-1-carboxyaldehyde; 2,4,6-trimethyl-3-cyclohexene-1-carboxyaldehyde; 3,5,6-trimethyl-3-cyclohexene-1-carboxyaldehyde; 6,10-dimethyl-3-oxa-9-undecenal; dimethyl benzyl carbinyl acetate; ethyl-(3aa,,4a,7a,3aa)-octahydro-4,7-methano-3aH indene-3a-carboxylate; 2-pentyl-3-methyl-2-cyclopenten-l-one; phenylhexanol; 1-(5,5-dimethyl-1-cyclohexen-1-yl)-4-penten-l-one; 6-tert-butyl-1,1-dimethylinden-4-yl methyl ketone; cis-4-isopropylcyclohexylmethanol; 1-allyl-3-methoxy-4-hydroxybenzene; - 48 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT (P2012-0780W000) Specification of PCT Application (E) -3,7-dimethyl-2,6-octadien-l-ol; 4-tert-butyl-2,6-dimethyl-3,5-dinitroacetophenone; 1,4-dioxacycloheptadecane-5,17-dione; hexyl salicylate; and a-methyl-3, 4 -methylenedioxyhydrocinnamic aldehyde.
    [6] 9. The method according to claim 8, which comprises applying at least one compound to an individual in need of reduction of the odor of the pyrazine derivative, in the presence of the odor of the pyrazine derivative.
    [7] 10. The method according to claim 9, wherein the at least one compound inhibits responses of an olfactory receptor ORSK1.
    [8] 11. The method according to any one of claims 8 to 10, wherein the pyrazine derivative is a compound represented by the following formula (I): R4 N: RI R3 N R2(I wherein R 1 represents methyl, ethyl, or acetyl; and R 2 , R 3 , and R 4 each independently represent hydrogen or methyl.
    [9] 12. The method according to claim 11, wherein at least one of R 1 to R 4 represents an alkyl group. - 49- WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application
    [10] 13. The method according to any one of claims 8 to 12, wherein the pyrazine derivative is selected from the group consisting of 2,6-dimethylpyrazine, 2,5 dimethylpyrazine, 2,3-dimethylpyrazine, 2,3,5 trimethylpyrazine, 2,3,5,6-tetramethylpyrazine, 2 monomethylpyrazine, 2-monoethylpyrazine, 2-ethyl-6 methylpyrazine, 3-methyl-2-acetylpyrazine, and 3,5 dimethyl-2-acetylpyrazine.
    [11] 14. The method according to any one of claims 8 to 13, wherein at least one compound is selected from the group consisting of the following compounds: 2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2 buten-1-ol; 5-methyl-2-(1-methylethyl)-phenol; 3,7-dimethyl-2,6-octadienal; phenylethyl salicylate; 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2 naphthalenyl)-ethanone; isolongifolanone; 4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one (a-ionone); 4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-2-one ($-ionone); vetiverol; 7-acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7 tetramethyl-naphthalene; a-amylcinnamic aldehyde; - 50 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application a-methyl-4-(1-methylethyl)-benzenepropanal; 4-methyl-3-decen-5-ol; and 1-(2-tert-butylcyclohexyloxy)-2-butanol.
    [12] 15. The method according to any one of claims 8 to 14, wherein the odor of the pyrazine derivative is an odor generated by reaction of a skin tanning agent with skin.
    [13] 16. An agent for reducing an odor of a pyrazine derivative, comprising at least one antagonist of olfactory receptor OR5K1 as an active ingredient, wherein the antagonist is selected from the group consisting of: 2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2 buten-1-ol; 5-methyl-2-(1-methylethyl)-phenol; 3,7-dimethyl-2,6-octadienal; phenylethyl salicylate; 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2 naphthalenyl)-ethanone; isolongifolanone; 4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one (u,-ionone); 4-(2,6,6-trimethyl-1l-cyclohexen-1-yl)-3-buten-2-one (P-ionone); vetiverol; 7-acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7 tetramethyl-naphthalene; a-amylcinnamic aldehyde; - 51 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application a-methyl-4-(1-methylethyl)-benzenepropanal; 4-methyl-3-decen-5-ol; 1-(2-tert-butylcyclohexyloxy)-2-butanol; 2-methoxy-l-(phenylmethoxy)-4-(1-propenyl)-benzene; a-methyl-p-(p-tert-butylphenyl)-propionaldehyde; 1 (-) -menthol; ow-6-hexadecenelactone; 2-(2-(4-methyl)-3-cyclohexen-1-yl) propylcyclopentanone; formaldehyde cyclododecyl ethyl acetal; 1-( 2 , 3 ,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-lH 3a,7-methanoazulen-5yl)-ethanone; -methyl naphthyl ketone; cedryl acetate; (5E)-3-methylcyclopenta-5-decen-l-one; cinnamaldehyde; 4-(i-ethoxyvinyl)-3,3,5,5-tetramethylcyclohexanone; a-hexylcinnamic aldehyde; 2-phenylpropionaldehyde; 3,7-dimethyl-6-octenal; dodecahydro-3a,6,6,9a-tetramethylnaphtho[2,1 b]furan; 4,7,7-trimethyl-spirobicyclo[2.2.1]heptane-2,1 cyclopentan-3-one; a-isomethyl ionone; 3,7-dimethyl-l-octanol; cedryl methyl ether; muscone; - 52 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application 2-methyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2 buten-1-ol; 2-cyclohexylpropanal; y-undecalactone; cyclopentadecanolide; 1-(2,6,6-trimethyl-1,3-cyclohexadien-1-yl)-2-buten 1-one; 2,4-dimethyl-3-cyclohexene-1-carboxyaldehyde; 2,4,6-trimethyl-3-cyclohexene-1-carboxyaldehyde; 3,5,6-trimethyl-3-cyclohexene-1-carboxyaldehyde; 6,10-dimethyl-3-oxa-9-undecenal; dimethyl benzyl carbinyl acetate; ethyl-(3aa,4cc,7a,3aa)-octahydro-4,7-methano-3aH indene-3a-carboxylate; 2-pentyl-3-methyl-2-cyclopenten-l-one; phenylhexanol; 1-(5,5-dimethyl-1-cyclohexen-1-yl)-4-penten-1-one; 6-tert-butyl-1,1-dimethylinden-4-yl methyl ketone; cis-4-isopropylcyclohexylmethanol; 1-allyl-3-methoxy-4-hydroxybenzene; (E)-3,7-dimethyl-2,6-octadien-1-ol; 4-tert-butyl-2,6-dimethyl-3,5-dinitroacetophenone; 1,4-dioxacycloheptadecane-5,17-dione; hexyl salicylate; and a-methyl-3,4-methylenedioxyhydrocinnamic aldehyde. - 53 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application
    [14] 17. The agent according to Claim 16, wherein the pyrazine derivative is a compound represented by the following Formula (I): R4: Nfq R1 Rf N R 2 (I) wherein R, represents methyl, ethyl or acetyl; and R 2 , R 3 and R 4 each independently represent hydrogen or methyl.
    [15] 18. The agent according to Claim 17, wherein at least one of R, to R 4 represents an alkyl group.
    [16] 19. The agent according to any one of Claims 16 to 18, wherein the pyrazine derivative is selected from the group consisting of 2,6-dimethylpyrazine, 2,5 dimethylpyrazine, 2,3-dimethylpyrazine, 2,3,5 trimethylpyrazine, 2,3,5,6-tetramethylpyrazine, 2 monomethylpyrazine, 2-monoethylpyrazine, 2-ethyl-6 methylpyrazine, 3-methyl-2-acetylpyrazine, and 3,5 dimethyl-2-acetylpyrazine.
    [17] 20. The agent according to any one of Claims 16 to 19, wherein the active ingredient is one or more compounds selected from the group consisting of: 2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2 buten-l-ol; 5-methyl-2-(1-methylethyl)-phenol; 3,7-dimethyl-2,6-octadienal; - 54 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application phenylethyl salicylate; 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2 naphthalenyl)-ethanone; isolongifolanone; 4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one (a-ionone); 4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-2-one (0-ionone); vetiverol; 7-acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7 tetramethyl-naphthalene; a-amylcinnamic aldehyde; a-methyl-4-(1-methylethyl)-benzenepropanal; 4-methyl-3-decen-5-ol; and 1-(2-tert-butylcyclohexyloxy)-2-butanol.
    [18] 21. The agent according to any one of Claims 16 to 20, wherein the agent is contained in a skin tanning agent.
    [19] 22. Use of at least one compound selected from the group consisting of the following compounds as an antagonist of olfactory receptor OR5K1: 2-ethyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2 buten-l-ol; 5-methyl-2-(1-methylethyl)-phenol; 3,7-dimethyl-2,6-octadienal; phenylethyl salicylate; - 55 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application 1-(5,6,7,8-tetrahydro-3,5,5,6,8,8-hexamethyl-2 naphthalenyl)-ethanone; isolongifolanone; 4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-3-buten-2-one (u.-ionone); 4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-buten-2-one (0-ionone); vetiverol; 7-acetyl-1,2,3,4,5,6,7,8-octahydro-1,1,6,7 tetramethyl-naphthalene; a-amylcinnamic aldehyde; a-methyl-4-(1-methylethyl)-benzenepropanal; 4-methyl-3-decen-5-ol; 1-(2-tert-butylcyclohexyloxy)-2-butanol; 2-methoxy-l-(phenylmethoxy)-4-(1-propenyl)-benzene; of-methyl- -(p-tert-butylphenyl)-propionaldehyde; l(-) -menthol; o-6-hexadecenelactone; 2-(2-(4-methyl)-3-cyclohexen-1-yl) propylcyclopentanone; formaldehyde cyclododecyl ethyl acetal; 1-(2,3,4,7,8,8a-hexahydro-3,6,8,8-tetramethyl-lH 3a,7-methanoazulen-5-yl)-ethanone; P-methyl naphthyl ketone; cedryl acetate; (5E)-3-methylcyclopenta-5-decen-l-one; cinnamaldehyde; 4-(l-ethoxyvinyl)-3,3,5,5-tetramethylcyclohexanone; - 56 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application a-hexylcinnamic aldehyde; 2-phenylpropionaldehyde; 3,7-dimethyl-6-octenal; dodecahydro-3a,6,6,9a-tetramethylnaphtho[2,1 b]furan; 4,7,7-trimethyl-spirobicyclo[2.2.llheptane-2,1 cyclopentan-3-one; a-isomethyl ionone; 3,7-dimethyl-1-octanol; cedryl methyl ether; muscone; 2-methyl-4-(2,2,3-trimethyl-3-cyclopenten-1-yl)-2 buten-1-ol; 2-cyclohexylpropanal; y-undecalactone; cyclopentadecanolide; 1-(2,6,6-trimethyl-1,3-cyclohexadien-1-yl)-2-buten 1-one; 2,4-dimethyl-3-cyclohexene-1-carboxyaldehyde; 2,4,6-trimethyl-3-cyclohexene-1-carboxyaldehyde; 3,5,6-trimethyl-3-cyclohexene-1-carboxyaldehyde; 6,10-dimethyl-3-oxa-9-undecenal; dimethyl benzyl carbinyl acetate; ethyl-(3aa,4a,7a,3aa)-octahydro-4,7-methano-3aH indene-3a-carboxylate; 2-pentyl-3-methyl-2-cyclopenten-1-one; phenylhexanol; 1-(5,5-dimethyl-1-cyclohexen-1-yl)-4-penten-1-one; - 57 - WO 2013/171535 PCT/IB2012/003131 KS1192PCT(P2012-0780W000) Specification of PCT Application 6-tert-butyl-1, 1-dimethylinden-4-yl methyl ketone; cis-4-isopropylcyclohexylmethanol; 1-allyl-3-methoxy-4-hydroxybenzene; (E) -3,7-dimethyl-2,6-octadien-l-ol; 4-tert-butyl-2,6-dimethyl-3,5-dinitroacetophenone; 1, 4-dioxacycloheptadecane-5, 17-dione; hexyl salicylate; and c-methyl-3, 4-methylenedioxyhydrocinnamic aldehyde. - 58 -
    类似技术:
    公开号 | 公开日 | 专利标题
    US10159655B2|2018-12-25|Agent for inhibiting odor of pyrazine derivatives
    EP2961374B1|2017-01-25|Fragrance compositions
    JP6243698B2|2017-12-06|Odor control by furaneol
    JP5798382B2|2015-10-21|Odor control agent
    JP5982044B2|2016-08-31|Odor control agent
    AU2014250625B2|2019-03-07|Inhibitor of odor caused by sotolone
    CN104125847B|2017-09-08|Perfume composition and application thereof
    EP3109307B1|2021-03-31|Perfume systems
    JP5646255B2|2014-12-24|Odor control agent
    US9057090B2|2015-06-16|Method of identifying an agent for inhibiting odor of pyrazine derivatives
    US9274102B2|2016-03-01|Method of screening for an inhibitor of odor cause by furaneol
    JP6182235B2|2017-08-16|Odor control agent
    AU2013250892B2|2017-05-04|Self-tanning cosmetic
    JP2020111555A|2020-07-27|Isovaleric acid odor inhibitor
    同族专利:
    公开号 | 公开日
    EP2812316B1|2016-08-17|
    US20130210775A1|2013-08-15|
    US10159655B2|2018-12-25|
    WO2013171535A3|2014-03-27|
    US20160317470A1|2016-11-03|
    EP2812316A2|2014-12-17|
    US20170258742A9|2017-09-14|
    WO2013171535A2|2013-11-21|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4622221A|1975-11-05|1986-11-11|Bush Boake Allen Inc.|Method, compositions and compounds, useful in room fresheners employing cyclohexyl alcohol and ester derivatives|
    US5135747A|1991-05-17|1992-08-04|Chesebrough-Pond's Usa Co., Division Of Conopco, Inc.|Deodorant/antiperspirant products with fragrance and encapsulated odor counteractant|
    US5272134A|1992-03-24|1993-12-21|Erox Corporation|Fragrance compositions and other compositions which contain human pheromones|
    EP0731717B1|1993-11-30|2002-07-31|Quest International B.V.|Anti-smoke perfumes and compositions|
    EP0760243B1|1995-08-31|2006-03-29|The Procter & Gamble Company|Use of allylic alcohol perfumes as a malodour reduction agent|
    US6086903A|1996-02-26|2000-07-11|The Proctor & Gamble Company|Personal treatment compositions and/or cosmetic compositions containing enduring perfume|
    GB2346900A|1999-02-18|2000-08-23|Reckitt & Colman Inc|Deodorizing compositions for fibrous substrates|
    JP4520682B2|1999-12-13|2010-08-11|シムライズ・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング・ウント・コンパニー・コマンジツト・ゲゼルシヤフト|Odor neutralizer|
    GB2359750A|2000-01-11|2001-09-05|Unilever Plc|Malodour treatment composition comprising acetal, ketal or cyclic triacetal obtained by reacting certain aldehydes/ketones with carbinols|
    GB0015470D0|2000-06-23|2000-08-16|Bush Boake Allen Ltd|Malodor counteractants and methods for preparing and using the same|
    WO2002035948A1|2000-11-06|2002-05-10|Japan Tobacco Inc.|Perfume compositions for deodorizing tobacco, tobacco deodorizing agents and cigarette and tobacco packages with little side smoke flow odor|
    US6610648B2|2000-12-22|2003-08-26|Givaudan Sa|Malodor counteractant compositions|
    GB0104094D0|2001-02-20|2001-04-04|Quest Int|Macrocyclic musks for malodour prevention and counteraction|
    JP5342727B2|2001-03-16|2013-11-13|高砂香料工業株式会社|Cigarette odor deodorant fragrance composition|
    JP2003024423A|2001-07-13|2003-01-28|Japan Tobacco Inc|Odor blocking agent for blocking odor of alkyl pyrazine compound|
    JP2003137758A|2001-10-29|2003-05-14|Kiyomitsu Kawasaki|Masking composition for hair cosmetic and hair cosmetic containing the same and method for masking hair cosmetic|
    US7344845B2|2001-12-21|2008-03-18|Senomyx, Inc.|Olfactory receptor for isovaleric acid and related malodorants and use thereof in assays for identification of blockers of malodor|
    ES2559764T3|2002-03-11|2016-02-15|Molecular Insight Pharmaceuticals, Inc.|Technetium dipyridine complexes, and methods of use thereof|
    JP2003339837A|2002-05-31|2003-12-02|S T Chem Co Ltd|Deodorizer and its composition|
    US20040223943A1|2003-05-05|2004-11-11|The Procter & Gamble Company|Air freshener|
    EP1781239A2|2003-11-17|2007-05-09|Patus Ltd|Compositions effective in altering the perception of malodor|
    JP2005325055A|2004-05-14|2005-11-24|Peptide Door Co Ltd|Ligand-binding protein-containing complex and method for screening substance binding to ligand-binding protein|
    CN101087879B|2004-06-18|2013-08-14|杜克大学|Modulators of odorant receptors|
    JP4388456B2|2004-10-29|2009-12-24|花王株式会社|Perfume composition for softener|
    US7585833B2|2005-02-17|2009-09-08|Givaudan Fragrances Corporation|Malodor covering perfumery|
    JP4965819B2|2005-05-26|2012-07-04|花王株式会社|Liquid deodorant composition|
    MX2008001708A|2005-08-02|2008-11-06|Wrigley W M Jun Co|Screening method for the identification of compositions suitable for the treatment of oral cavity malodor associated with smoking a tobacco product.|
    EP1884555A2|2006-08-01|2008-02-06|Symrise GmbH & Co. KG|Masking mineral oil smell and scenting of mineral oils|
    EP2059265B1|2006-08-28|2018-10-17|Firmenich S.A.|Malodor counteracting compositions and method for their use|
    CN101528272A|2006-10-24|2009-09-09|吉万奥丹股份有限公司|Malodor counteracting compositions|
    EP2133102B1|2008-03-19|2014-12-03|Symrise AG|Odor reducers|
    JP5690467B2|2008-04-11|2015-03-25|花王株式会社|Screening method for olfactory sensitivity inhibitor|
    EP2110118B1|2008-04-15|2014-11-19|Takasago International Corporation|Malodour reducing composition and uses thereof|
    US8506943B2|2009-07-16|2013-08-13|International Flavors & Fragrances Inc.|Cyclohexylethyl carboxylic acid ester compositions and method for using the same for reducing malodors|
    US8741275B2|2010-06-04|2014-06-03|Robetet, Inc.|Malodor neutralizing compositions comprising undecylenic acid or citric acid|
    JP5697383B2|2010-09-03|2015-04-08|花王株式会社|Search method for malodor control agent|
    JP5646255B2|2010-09-03|2014-12-24|花王株式会社|Odor control agent|
    WO2012029922A1|2010-09-03|2012-03-08|花王株式会社|Method for searching for malodor control agent, malodor control agent, and malodor control method|
    US20130210775A1|2012-02-09|2013-08-15|Kao Corporation|Agent for inhibiting odor of pyrazine derivatives|JP5593271B2|2011-06-06|2014-09-17|花王株式会社|Search method for malodor control agent|
    US20130210775A1|2012-02-09|2013-08-15|Kao Corporation|Agent for inhibiting odor of pyrazine derivatives|
    WO2013156859A2|2012-04-20|2013-10-24|Kao Corporation|Self-tanning cosmetic|
    JP6041706B2|2013-02-28|2016-12-14|昭和産業株式会社|Composition for cooking microwave oven for chicken and method for suppressing unpleasant odor of chicken by microwave cooking using the composition for cooking microwave oven for chicken|
    JP6276555B2|2013-10-22|2018-02-07|花王株式会社|Search method of odor control agent by furaneol|
    JP6243698B2|2013-10-22|2017-12-06|花王株式会社|Odor control by furaneol|
    CN103936758A|2014-02-21|2014-07-23|温州医科大学|Biotin labeled ligustrazine and preparation method thereof|
    US20190343977A1|2016-11-18|2019-11-14|Firmenich Sa|Use of volatile compositions to limit or eliminate perception of fecal malodour|
    法律状态:
    2016-05-12| MK1| Application lapsed section 142(2)(a) - no request for examination in relevant period|
    优先权:
    申请号 | 申请日 | 专利标题
    US201261596963P| true| 2012-02-09|2012-02-09||
    US61/596,963||2012-02-09||
    PCT/IB2012/003131|WO2013171535A2|2012-02-09|2012-12-29|Agent for inhibiting odor of pyrazine derivatives|
    [返回顶部]